Statement: FDA Must Reject Tanezumab as a Treatment for Osteoarthritis Due to Unacceptable Dangers, Little to No Benefit
Letter to Congress Offering Health Care-Related Reforms for Possible Inclusion in Future Cures 2.0 Legislation December 16, 2019